Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 11/20 | 0.64 |
| ▸ | AURKB | Q96GD4 | 10/20 | 0.64 |
| ▸ | SRC | P12931 | 3/20 | 0.56 |
| ▸ | MET | P08581 | 3/20 | 0.49 |
| ▸ | PRKDC | P78527 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.46 |
| ▸ | CDK2 | P24941 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.46 |
| ▸ | KDR | P35968 | 1/20 | 0.46 |
| ▸ | AKT2 | P31751 | 1/20 | 0.45 |
| ▸ | FLT3 | P36888 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3798297 | 1.00 | AURKA (0.64) | AURKAAURKBSRCMETPRKDC | |
| SCHEMBL3802699 | 0.88 | AURKA (0.68) | AURKAAURKBMETPRKDCFGFR1 | |
| SCHEMBL3802701 | 0.88 | AURKA (0.68) | AURKAAURKBMETPRKDCFGFR1 | |
| SCHEMBL7263736 | 0.85 | AURKA (0.72) | AURKAAURKBPRKDCFGFR1KDR | |
| SCHEMBL3812985 | 0.84 | MET (0.57) | AURKAAURKBSRCMETPRKDC | |
| SCHEMBL3801841 | 0.84 | AURKA (0.90) | AURKAAURKBSRC | |
| SCHEMBL3801848 | 0.84 | AURKA (0.90) | AURKAAURKBSRC | |
| SCHEMBL3800843 | 0.83 | AURKA (0.74) | AURKAAURKBSRCMETPTK2B | |
| SCHEMBL3800849 | 0.83 | AURKA (0.74) | AURKAAURKBSRCMETPTK2B | |
| SCHEMBL3805989 | 0.82 | MET (0.75) | AURKAAURKBSRCMETMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7897602-B2 | Indolinone compounds as kinase inhibitors | DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) | 2011-03-01 | — | — | US | claimed |
| US-20100179146-A1 | Indolinone Compounds as Kinase Inhibitors | DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) | 2010-07-15 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179146-A1 | Indolinone Compounds as Kinase Inhibitors | CDK2, MAP3K19, MAP3K20 | AURKA 96/4885AURKB 69/4885SRC 394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.